Nedosiran 80 mg, 160 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 80 mg, 160 mg

Reference Brands: Ryplazim (USA)

Category: Nephrology

Nedosiran is a Nephrology product available as Injection in strengths 80 mg, 160 mg. It corresponds to the reference brand Ryplazim (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Nedosiran, marketed under the brand name Rivfloza, is a targeted RNA interference (RNAi) therapy used for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder characterized by excessive oxalate production that can progressively damage the kidneys. Developed by Dicerna Pharmaceuticals, nedosiran is an LDHA-directed small interfering RNA that specifically silences the hepatic lactate dehydrogenase A (LDHA) gene, reducing oxalate synthesis at its source.

Rivfloza is indicated for patients aged nine years and older with PH1 who have relatively preserved kidney function. By lowering urinary oxalate levels, nedosiran helps prevent kidney stone formation, nephrocalcinosis, and long-term renal complications associated with the disease. The therapy is administered via subcutaneous injection, typically on a monthly or individualized dosing schedule, providing a convenient and precise approach to managing this rare metabolic condition.

Through its innovative RNAi mechanism, Rivfloza offers a disease-modifying option for patients with PH1, addressing the underlying cause of oxalate overproduction rather than just managing symptoms. Its targeted action, combined with clinical efficacy and favorable safety profile, positions nedosiran as a significant advancement in the treatment of primary hyperoxaluria, improving patient outcomes and long-term kidney health.